SkinBioTherapeutics PLC
Inflection Points - Turning a Corner with Breakthrough Potential
By Alex Langton | 17 April 2025
Mike, Elric, and I have a financial interest in SkinBioTherapeutics.
Father, aka the ‘old duffer’ was up into the small hours hammering on the keyboard, updating Fresnillio and Journeo, for the Small Company Champion side. Both companies are going great guns. On to SkinBioTherapeutics, so you have to suffer me today. The main focus will be on potential inflection points we deliberately ignored in our article yesterday, because, as you could see, Zenakine™ needed special care and attention.
After a protracted period of uncertainty, SkinBioTherapeutics appears to have decisively recalibrated its trajectory, emerging with renewed vigour and a commercially potent proposition at its core. For investors who tuned into the company’s latest presentation hosted by IMC, and indeed, we believe HNWI investors and institutions have been provided separate presentations, the message from Dr Surinder 'Dass' Chahal was unequivocal: the future of skincare may well be written in the name Zenakine™. The standing ovation received at its recent technical launch at in-cosmetics Global in Amsterdam was no mere formality; it marked the arrival of a disruptive ingredient that has set the cosmetics industry abuzz.
Zenakine™: Neurocosmetics Redefined
Positioned at the vanguard of neuroactive skincare, Zenakine™ is not merely another active—rather, it signals a paradigm shift. Developed in collaboration with Croda, one of the industry’s most sophisticated operators, the ingredient has shown clinically validated results in mitigating cortisol-induced damage, recalibrating the skin's circadian rhythm, and delivering profound anti-ageing outcomes. These attributes, which straddle both physical rejuvenation and emotional well-being, offer a compelling value proposition to high-end formulators seeking differentiation in an increasingly crowded market.
Croda’s early commercial mobilisation of Zenakine™, coupled with its distribution firepower, sets the stage for a swift and broad-based market adoption. It is entirely plausible, given early indicators, that Zenakine™ could be incorporated into formulations from major global cosmetics brands within the next 18 months—paving the way for annualised gross profits to enter seven-figure territory by the close of FY2026.
Clarity on Capital: A Stronger Financial Base